IMDX - NASDAQ

Insight Molecular Diagnostics Inc.

IMDX·NASDAQ

$6.61

+17%

HealthcareMedical - Diagnostics & Research

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$177.42M

EPS-1.6500

P/E Ratio-4.01

Earnings Date08/10/2026

25.76M

Assets

-27%

3Y-74.0%

5Y-54.0%

10Y+78.0%

57.22M

Total Liabilities

21%

3Y-5.0%

5Y+161.0%

10Y+1148.0%

-31.46M

Total Equity

156%

3Y-179.0%

5Y-194.0%

10Y-419.0%

Insight Molecular Diagnostics Inc. Funding & Solvency Profile

IMDX · NASDAQ

Current Assets

Cash & Cash Equivalents11.58M

Net Receivables1.13M

Inventory446.00K

Other Current Assets2.15M

Total Current Assets15 M

Non-Current Assets

Property, Plant & Equipment2.81M

Goodwill & Intangible Assets0.00

Long-Term Investments607.00K

Other Non-Current Assets7.03M

Total Non-Current Assets10 M

Total Assets

25.76M

Financial Health Analysis

Current Ratio

1.27x

Acceptable liquidity, but monitor closely. Current assets just barely cover current liabilities.

Working Capital

3 M

Positive working capital, but relatively tight. The company should monitor cash flow carefully.

Asset Composition

59% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

Insight Molecular Diagnostics Inc. Balance Sheet

IMDX • NASDAQ

Insight Molecular Diagnostics Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	11.6M	8.6M	9.4M	20M	32.9M	7.1M	22.1M	8M	7.6M	10.2M	8M	257K	101K
Short-Term Investments	0.0	0.0	0.0	433K	904K	675K	379K	428K	760K	2.2M	2.5M	3.3M	4.6M
Cash & Short-Term Investments	11.6M	8.6M	9.4M	20.4M	33.9M	7.8M	22.5M	8.5M	8.4M	12.4M	10.5M	3.5M	4.7M
Net Receivables	1.1M	1.6M	484K	2M	1.4M	203K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accounts Receivables	1.1M	1.6M	484K	2M	1.4M	203K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	446K	410K	0.0	0.0	304K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	0.0	977K	608K	264K	80K	102K	168K	285K	19K	114K	120K
Other Current Assets	2.1M	1.1M	782K	2.1M	2.9M	941K	425K	180K	168K	285K	366K	0.0	0.0
Total Current Assets	15.3M	11.8M	10.7M	25.5M	39.1M	9.2M	23M	8.6M	8.5M	12.7M	10.9M	3.7M	4.9M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	2.8M	2.8M	5.4M	10.9M	8.4M	6.5M	3.7M	614K	822K	688K	576K	118K	148K
Goodwill	0.0	0.0	0.0	0.0	18.7M	9.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Intangible Assets	0.0	14.6M	56.6M	61.6M	61.7M	15M	0.0	0.0	746K	988K	1.2M	1.5M	1.7M
Goodwill & Intangible Assets	0.0	14.6M	56.6M	61.6M	80.4M	24.2M	0.0	0.0	746K	988K	1.2M	1.5M	1.7M
Long-Term Investments	607K	1.7M	0.0	0.0	0.0	13.4M	11M	0.0	0.0	0.0	0.0	0.0	-1.6M
Tax Assets	0.0	0.0	0.0	0.0	0.0	118K	0.0	0.0	0.0	0.0	0.0	1.1M	1.6M
Other Non-Current Assets	7M	4.3M	2.2M	2.1M	31.6M	1.9M	2.2M	262K	120K	75K	0.0	0.0	1.6M
Total Non-Current Assets	10.5M	23.3M	64.2M	74.6M	120.4M	46.2M	16.9M	876K	1.7M	1.8M	1.8M	2.7M	3.4M
Total Assets	25.8M	35.1M	74.9M	100.1M	159.6M	55.4M	39.9M	9.5M	10.2M	14.4M	12.7M	6.4M	8.3M
LIABILITIES
CURRENT LIABILITIES
Total Payables	2.5M	2.3M	953K	1.3M	1.8M	432K	475K	166K	175K	3.3M	285K	144K	103K
Accounts Payable	2.5M	2.3M	953K	1.3M	1.8M	432K	469K	166K	175K	422K	285K	144K	103K
Other Payables	0.0	0.0	0.0	0.0	0.0	0.0	6K	0.0	0.0	-422K	0.0	0.0	0.0
Accrued Expenses	0.0	1.5M	1.6M	5.6M	3.5M	5.8M	1.3M	806K	406K	549K	325K	147K	32K
Short Term Debt	1.8M	0.0	0.0	0.0	1.3M	2.4M	1.4M	1.2M	1.1M	202K	0.0	5.9M	3M
Capital Lease Obligations (Current)	0.0	1.3M	665K	815K	819K	422K	230K	385K	338K	202K	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-847K	0.0	0.0
Other Current Liabilities	7.7M	2.2M	4M	4.4M	6.7M	0.0	1.1M	3M	2.4M	46K	1.7M	1.3M	1.6M
Total Current Liabilities	12.1M	7.3M	7.2M	12.1M	14.1M	9M	4.4M	5.6M	4.5M	4.3M	2.3M	7.4M	4.7M
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	1.5M	1.9M	347K	1.1M	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	43.5M	37.7M	45M	45.7M	76.7M	7.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Non-Current Liabilities	45.1M	40.1M	47.2M	48.4M	80.2M	12.9M	4.6M	534K	1.4M	310K	0.0	0.0	0.0
Capital Lease Obligations	1.7M	3.7M	2.9M	3.5M	4.4M	4.7M	2.9M	572K	627K	512K	0.0	0.0	0.0
Total Liabilities	57.2M	47.4M	54.4M	60.5M	94.3M	21.9M	9M	6.1M	5.8M	4.6M	2.3M	7.4M	4.7M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	5.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Common Stock	369.2M	338.2M	310.3M	294.9M	253M	157.2M	124.6M	74.7M	60M	45.8M	34.9M	15.1M	15.4M
Retained Earnings	-400.8M	-350.5M	-289.9M	-260.7M	-187.8M	-123.7M	-93.7M	-71.3M	-54.7M	-35.3M	-24.1M	-15.4M	-10.4M
Accumulated Other Comprehensive Income/Loss	86K	21K	49K	39K	37K	0.0	0.0	0.0	-888K	-654K	-350K	-822K	-1.4M
Total Stockholders' Equity	-31.5M	-12.3M	20.5M	39.6M	65.2M	33.5M	30.8M	3.4M	4.4M	9.9M	10.4M	-1.1M	3.6M
Total Equity	-31.5M	-12.3M	20.5M	39.6M	65.2M	33.5M	30.8M	3.4M	4.4M	9.9M	10.4M	-1.1M	3.6M
SUMMARY
Total Liabilities & Equity	25.8M	35.1M	74.9M	100.1M	159.6M	55.4M	39.9M	9.5M	10.2M	14.4M	12.7M	6.4M	8.3M
Total Investments	607K	1.7M	0.0	433K	904K	14.1M	11.3M	428K	760K	2.2M	2.5M	3.3M	4.6M
Total Debt	3.5M	3.7M	2.9M	3.5M	5.7M	8.6M	5.9M	1.7M	2.5M	512K	847K	5.9M	3M
Net Debt	-8.1M	-5M	-6.6M	-16.4M	-27.3M	1.5M	-16.1M	-6.3M	-5.1M	-9.7M	-7.1M	5.6M	2.9M
Shares Outstanding	28,606,595	28,606,595	28,606,595	28,606,595	28,606,595	28,606,595	28,606,595	28,606,595	28,606,595	28,606,595	28,606,595	28,606,595	28,606,595

SEC Filings

IMDX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K/A 8-K/A 2026 (Amended) N/A	May 13, 2026	February 20, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 13, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 13, 2026	May 13, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 30, 2026	April 30, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 30, 2026	April 30, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 26, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 26, 2026	March 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 26, 2026	February 20, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 12, 2026	February 10, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 11, 2026	February 11, 2026	2026	View Filing

Showing 1 to 10 of 257 filings

Related Guides

Blog Categories

Continue your IMDX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.